Artwork

Content provided by Joel Topf and NephJC Team. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Topf and NephJC Team or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 72: Nefecon for IgAN, The NefIgArd part B trial

1:32:16
 
Share
 

Manage episode 423749668 series 2540759
Content provided by Joel Topf and NephJC Team. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Topf and NephJC Team or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The Filtrate:

Joel Topf

Josh Waitzman

With Special Guest:

Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial.

Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North Carolina

Roger Rodby (@NephRodby) Associate program director of the Rush University Nephrology Fellowship

Editor

Sophia Ambruso

Show Notes

The manuscript (The Lancet | PubMed | NephJC)

The Results of Part A (Kidney Int | PubMed)

Edmund (Ed) Louis memorium by Steve Korbet in KI

Steve Korbet Do not miss this tweet

TESTING Freely Filtered #48 with Sean Barbour

Iptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN Study

FDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)

Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)

Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)

MEST Scores in NephJC

Risk scores in IgAN in NephJC

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)

Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)

IgA nephropathy in African Americans: uncommon but possible (PubMed Central)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know (PubMed Central)

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)

Tubular Secretions

Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (Audible)

Josh: Podcasts about donating a kidney

One Is Enough Podcast (National Kidney Registry)

Donor Diaries (National Kidney Donation Organization)

Roger Iceland (Wikipedia)

Koyal India (Wikipedia)

Brad Fishing in Dubai

  continue reading

72 episodes

Artwork
iconShare
 
Manage episode 423749668 series 2540759
Content provided by Joel Topf and NephJC Team. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Joel Topf and NephJC Team or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The Filtrate:

Joel Topf

Josh Waitzman

With Special Guest:

Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial.

Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North Carolina

Roger Rodby (@NephRodby) Associate program director of the Rush University Nephrology Fellowship

Editor

Sophia Ambruso

Show Notes

The manuscript (The Lancet | PubMed | NephJC)

The Results of Part A (Kidney Int | PubMed)

Edmund (Ed) Louis memorium by Steve Korbet in KI

Steve Korbet Do not miss this tweet

TESTING Freely Filtered #48 with Sean Barbour

Iptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN Study

FDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)

Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)

Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)

MEST Scores in NephJC

Risk scores in IgAN in NephJC

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)

Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)

IgA nephropathy in African Americans: uncommon but possible (PubMed Central)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know (PubMed Central)

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)

Tubular Secretions

Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (Audible)

Josh: Podcasts about donating a kidney

One Is Enough Podcast (National Kidney Registry)

Donor Diaries (National Kidney Donation Organization)

Roger Iceland (Wikipedia)

Koyal India (Wikipedia)

Brad Fishing in Dubai

  continue reading

72 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide